Alphanox to Acquire Additional Shares of U.S. Subsidiary for 5.6 Billion KRW
Alphanox announced on the 19th that it will acquire an additional 4 million shares of its U.S. implant sales subsidiary (Solco Biomedical) for approximately 5.6 billion KRW.
After the acquisition, Alphanox's ownership stake will become 100%. The scheduled date of share acquisition is the 23rd.
Hot Picks Today
“It Wasn’t Vietnam”... Average Travel Cost 1.33 Million Won, Japan Tops Chuseok Holiday Destinations
- Venerable Myungjin, Former Head Monk of Bongeunsa Temple, Passes Away in Freediving Accident off Jeju Coast
- "This Is the Korean Hit Item"... Olive Young Expands Across the U.S. [Report]
- "Unimaginable Outside Korea": Taiwanese Tourist Recovers 1.3 Million Won Left in Taxi
- "Could Have Led to a Serious Accident": Public Outrage as Spectator Pushes Mascot at Baseball Stadium... Father Apologizes
The company stated that the purpose of this acquisition is to strengthen business competitiveness in the U.S. market and to improve its financial structure.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.
